» 
Rikke Winther

Rikke Winther

MSc in Pharmacy from Copenhagen University

Role in PharmNovo: Clinical outsourcing lead.

Company: WIN Outsourcing Consult.

Resumé: Rikke is highly specialized and globally experienced within Pre-clinical and Clinical R&D, Business Development and Contract/Outsourcing Management and has worked in the CRO and Pharmaceutical industry within these fields for more than 25 years.

For almost two decades, she headed up the R&D Outsourcing & Contracts Management R&D function at Lundbeck where she was globally responsible for all R&D outsourcing matters covering contractual, operational and relationship related activities with all CROs/vendors as well as complex research collaborations agreements with academia. Rikke has significant experience in developing and executing a broad variety of outsourcing strategies and is a strong negotiator with a win-win approach to retaining positive relationships with all stakeholders.

Prior to her employment at Lundbeck, Rikke worked for five years within bio-analytical research and clinical development in hospital/academia settings. This was followed by four years of employment in a larger CRO (International Project Manager followed by setting up the CRO’s first South East Asia office working as Business Development Manager and Line Manager in Singapore).

Rikke has since 2013 been a Steering Committee member of the Pharmaceutical Contract Management Group (PCMG.org.uk) in Europe.

Member of:

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more